Pioneering a game-changing approach to prevent cancer recurrence and progression, the primary unmet medical need in oncology, responsible for 90% of cancer deaths. Our proprietary platform finds drugs that disable the seeds of cancer recurrence before they cause deadly metastatic tumors was used to identify lead therapy, VUJ-100, entering a Phase 1/2 clinical trial in 2024 via non-dilutive funding & collaboration with leading US hospitals